Table 2.
Comparison of survivors and patients who died during the period of follow-up.
| Survivors (N = 128) | Death (N = 89) | p | |
|---|---|---|---|
| Age (years) | 69 ± 10 | 76 ± 12 | <0.001 |
| Sex (men/women) | 59/69 | 40/49 | 0.87 |
| Previous stroke or transient ischemic attack (n/%) | 24 (18.7) | 18 (20.2) | 0.79 |
| Concomitant diseases | |||
| Hypertension (n (%)) | 109 (85.2) | 77 (86.5) | 0.78 |
| Ischemic heart disease (n (%)) | 31 (24.2) | 32 (36.0) | 0.06 |
| Atrial fibrillation (n (%)) | 31 (24.2) | 35 (39.3) | <0.05 |
| Obesity (n (%)) | 24 (18.8) | 18 (20.2) | 0.79 |
| Diabetes (n (%)) | 42 (32.8) | 37 (41.6) | 0.19 |
| Hypercholesterolemia (n (%)) | |||
| Medications before stroke | |||
| Aspirin (n (%)) | 28 (45.7) | 49 (55.7) | 0.15 |
| Statin therapy (n (%)) | 47 (36.7) | 37 (41.6) | 0.47 |
| Antithrombotic agents (n (%)) | 15 (11.7) | 12 (13.5) | 0.70 |
| Addictions | |||
| Active smokers (n (%)) | 31 (24.2) | 14 (15.7) | 0.13 |
| Addicted to alcohol (n (%)) | 4 (3.1) | 6 (6.7) | 0.32 |
| Type of stroke | |||
| Large vessel occlusion (n (%)) | 62 (48.4) | 44 (49.4) | <0.05 |
| Lacunar (n (%)) | 41 (32.1) | 15 (16.9) | |
| Embolic (n (%)) | 25 (19.5) | 30 (33.7) | |
| Stroke severity | |||
| NIHSS-I score | 7.3 ± 5.2 | 11.5 ± 7.1 | <0.001 |
| Laboratory findings | |||
| Total cholesterol (mmol/L) | 5.22 ± 1.62 | 4.85 ± 1.31 | 0.07 |
| LDL cholesterol (mmol/L) | 3.33 ± 1.33 | 2.98 ± 1.11 | <0.05 |
| HDL cholesterol (mmol/L) | 1.38 ± 0.36 | 1.43 ± 0.51 | 0.44 |
| Triglycerides (mmol/L) | 1.59 (1.15–2.28) | 1.23 (0.96–1.56) | <0.001 |
| Creatinine (μmol/L) | 78.9 (69.0–89.2) | 84.4 (72.9–99.1) | 0.08 |
| Estimated glomerular filtration rate—eGFR (mL/min/1.73 m2) | 72.9 ± 24.4 | 65.0 ± 24.6 | <0.05 |
| CKD (eGFR < 60 mL/min/1.73 m2 or albuminuria) (n (%)) | 41 (32.0) | 39 (43.8) | 0.08 |
| C-reactive protein (mg/dL) | 3.82 (1.60–9.21) | 4.22 (2.09–9.36) | 0.30 |
| Calcium (mg/dL) | 2.30 (2.18–2.45) | 2.29 (2.20–2.45) | 0.69 |
| Phosphorus (mg/dL) | 1.13 (0.98–1.38) | 1.11 (0.93–1.32) | 0.62 |
| Intact parathyroid hormone (pg/mL) | 37.3 (22.8–54.2) | 42.6 (29.7–65.1) | 0.08 |
| Intact fibroblast growth factor 23—iFGF23 (pg/mL) | 54.3 (17.6–86.2) | 51.5 (25.3–84.9) | 0.48 |
| Soluble α-Klotho (pg/mL) | 627.1 (386.6–870.2) | 689.3 (470.8–983.6) | 0.18 |
| Klotho/iFGF23 | 11.5 (6.5–30.5) | 14.4 (7.7–26.7) | 0.89 |
Mean ± standard deviation or median (lower quartile-upper quartile).